Technical Analysis for NTBL - Notable Labs, Ltd.

Grade Last Price % Change Price Change
F 0.05 137.62% 0.03
NTBL closed up 137.62 percent on Wednesday, November 20, 2024, on 1 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 137.62%
NR7 Range Contraction 137.62%
Narrow Range Bar Range Contraction 137.62%
Doji - Bullish? Reversal 137.62%
Lower Bollinger Band Walk Weakness 137.62%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Notable Labs, Ltd. Description

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cancer Treatment Acute Myeloid Leukemia Orphan Drug Protein Kinase Inhibitor Myelodysplastic Syndrome Chronic Myeloid Leukemia Kinase 1 Lintuzumab

Is NTBL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.24
52 Week Low 0.0201
Average Volume 3,255,751
200-Day Moving Average 0.87
50-Day Moving Average 0.39
20-Day Moving Average 0.24
10-Day Moving Average 0.13
Average True Range 0.06
RSI (14) 27.01
ADX 19.29
+DI 27.38
-DI 35.62
Chandelier Exit (Long, 3 ATRs) 0.48
Chandelier Exit (Short, 3 ATRs) 0.21
Upper Bollinger Bands 0.52
Lower Bollinger Band -0.03
Percent B (%b) 0.15
BandWidth 226.62
MACD Line -0.10
MACD Signal Line -0.08
MACD Histogram -0.021
Fundamentals Value
Market Cap 432.06 Thousand
Num Shares 9 Million
EPS -1.61
Price-to-Earnings (P/E) Ratio -0.03
Price-to-Sales 90.01
Price-to-Book 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.09
Resistance 3 (R3) 0.09 0.07 0.08
Resistance 2 (R2) 0.07 0.06 0.07 0.08
Resistance 1 (R1) 0.06 0.05 0.06 0.06 0.08
Pivot Point 0.04 0.04 0.04 0.04 0.04
Support 1 (S1) 0.03 0.03 0.03 0.03 0.02
Support 2 (S2) 0.01 0.02 0.01 0.02
Support 3 (S3) 0.00 0.01 0.01
Support 4 (S4) 0.01